Balaxi Pharmaceuticals Limited
Income Statement

Last updated:

Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Balaxi Pharmaceuticals Limited's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 14% to $2,412,944,000. Profit margin reached -1%. Total operating expenses were $656,744,000.

Profit Margin

Balaxi Pharmaceuticals Limited (NSE:BALAXI.NS): Profit margin
2015 1.23M 1.02M 82.71%
2016 475.11K -803.72K -169.17%
2018 -500 -7.71M 1543860%
2019 135.95M 19.65M 14.46%
2021 2.31B 381.37M 16.49%
2022 2.79B 476.57M 17.06%
2024 2.41B -23.87M -0.99%

BALAXI.NS Income Statement (2014 – 2023)

2023 2021 2020 2018 2017 2015 2014
Revenue
Revenue
2.41B2.79B2.31B135.95M-500475.11K1.23M
Cost of revenue
1.28B1.95B1.72B104.69M19.4K841.43K13.9K
Gross profit
1.12B837.91M591.85M31.25M-19.9K-366.32K1.22M
Operating exp.
Research and development
000015.39K00
Selling and marketing
6.55M10.21M1.01M154.4K253.3K34.18K72.76K
Total operating expenses
656.74M334.80M167.68M14.93M7.39M1.18M803.80K
Operating income
467.30M546.63M443.84M16.31M-7.67M-694.83K1.60M
Other income (expenses), net
-447.15M-1.41M-555K8.07M-20.4K-468.30K-641.05K
Income before tax
20.15M545.22M443.29M24.39M-7.69M-1.16M1.47M
Income tax expense
44.02M68.64M61.91M4.73M20.4K-359.40K447.92K
Net income
-23.87M476.57M381.37M19.65M-7.71M-803.72K1.02M
Earnings per share
Basic EPS
-0.4647.667.636.47-0.51-0.050.1
Diluted EPS
-0.4647.667.636.47-0.51-0.050.1
Data sourceData sourceData sourceData sourceData sourceData sourceData source